

Phi Pharma Enlarges Team with CEO and Head of Chemistry Appointments

December 14, 2016, Geneva, Switzerland. Phi Pharma SA, a Swiss biotherapeutics company developing peptide drug conjugates as targeted drugs in oncology, auto-immune disease and infectious disease, announced today the appointment of Dr Tom Shepherd as Chief Executive Officer and Dr Andreas Peer as Head of Chemistry.

Dr Shepherd has over 30 years' experience in the biotechnology and pharmaceutical industries, including senior management roles in the USA, UK, France and Australia where he led multiple pharmaceutical asset and technology licensing transactions and has been responsible for strategic company-building acquisitions.

Dr Shepherd formerly held CEO positions in Bioaster (France), Neurotech (France and USA), CXR Biosciences (UK) as well as Vice President or Chief Business Officer posts at Kymab (UK), Valeant Pharmaceuticals (USA) and Intrabiotics Pharmaceuticals (USA). Dr. Shepherd was awarded a Ph.D. in biochemistry from the University of Strathclyde in Scotland and completed the Continuing Executive Programme at the London Business School.

Emmanuel Savioz, co-founder and Chairman of the Board of Phi Pharma said, "The announcement today of the appointment of Dr Shepherd is a key milestone for Phi and brings the high-level, international leadership skills required to pilot the company through its next phase of development towards our first clinical studies."

Dr Shepherd commented, "Phi Pharma has a very exciting, novel product platform with the potential to transform that way several cancers are treated and I am delighted to join Phi Pharma at this opportune time in its development. As a key step in completing the management team, Phi Pharma can also announce today the appointment of the hugely experienced industrial scientist, Dr Andreas Peer, who will lead the chemistry effort."

Dr Peer has a long track record of achievement in the pharmaceutical and biotechnology industry managing R&D and development projects at Genzyme, Lonza and CordenPharma. He has been responsible for API development programs for peptide and carbohydrate pharmaceuticals in preclinical and clinical phases and managed CRO and CMO activities for drug substance CMC. Dr Peer holds a PhD in organic chemistry from the ETH in Zürich and completed post-doctoral programs at the EPF in Lausanne and McGill in Montréal.

About Phi Pharma

Phi Pharma SA is a private Swiss-based biopharmaceutical company. It specializes in the discovery and early development of peptide drug conjugates for improving the treatment of diseases with high unmet medical needs. The Phi Pharma technology is based on a powerful new class of peptide drug conjugates with specific cellular targeting and efficient intra-cellular delivery. The lead programs are in oncology and infectious diseases.

Media Contact:

Dr Tom Shepherd, Chief Executive Officer

Email: tom.shepherd@phi-pharma.com

Web: <http://www.phi-pharma.com>